The U.S. asthma and COPD drugs market size accounted at USD 12.93 billion in 2025 and is predicted to increase from USD 13.51 billion in 2026 to approximately USD 20.08 billion by 2035, expanding at a CAGR of 4.5% from 2026 to 2035. Increasing respiratory disease, rise in the demand for advanced drug delivery technologies, growing geriatric population, increasing demand for biologics, expanding R&D activities, and growing health awareness are promoting the market growth.
The asthma and COPD drugs encompass the medications developed, manufactured, and distributed for the treatment of asthma and COPD across the U.S. They are used for relieving symptoms, preventing airway inflammation, and managing long-term respiratory disease. They are also used as emergency respiratory cases and maintenance therapy for chronic lung conditions.
The graph represents a comparison between American asthma patients. It indicates that there will be a rise in asthma cases, which will drive the demand for their effective treatment and management solutions. This, in turn, will increase the adoption of asthma and COPD drugs across the U.S., which will ultimately promote the market growth.
By drug class type, the bronchodilators segment accounted for the highest revenue share of 34% U.S. asthma and COPD drugs market in 2025, due to growth in the asthma and COPD cases. Their quick airway relaxation also increased their use as a first-line treatment option. Their widespread availability also increased their adoption rates.
By disease type, the asthma segment held a major revenue share of 46% of the U.S. asthma and COPD drugs market in 2025, due to growth in the incidence rates. Increased health awareness and government initiatives also increased the demand for asthma and COPD drugs across the U.S. Growth in the demand for biologics and targeted therapies also increased their adoption.
By distribution channel type, the retail pharmacies segment contributed the biggest revenue share of 45% of the U.S. asthma and COPD drugs market in 2025, driven by their widespread availability. The availability of prescription and OTC drugs also increased their acceptance rates. Their patient counselling and insurance coverage also increased their use.
By end user, the hospitals segment held the largest revenue share of 39% of the U.S. asthma and COPD drugs market in 2025, due to a high volume of asthma and COPD patients. The presence of advanced respiratory therapies and specialized pulmonologists also attracts the patients. Long-term monitoring and emergency care services also increased their acceptance rates.
The U.S. asthma and COPD drugs market held 78.8% share and is expected to show significant growth during the forecast period, due to growth in the asthma and COPD patient volume. High health awareness and healthcare spending also increased the adoption of asthma and COPD drugs. Favourable reimbursement policies, major players, and advanced healthcare infrastructure also contributed to the market growth.
GlaxoSmithKline dominated the market with its Advair, Trelegy Eilipta, Ventolin, and Breo Ellipta, where AstraZeneca was its closest competitor, which offers Symbicort, Fasenra, and Pulmicort. Boehringer Ingelheim also maintained its standing by providing Spiriva, Stiolto Respimat, and Combivent Respimat, where Teva Pharmaceuticals also contributed to the market growth with its ProAir HFA, Qvar RediHaler, and ProAir Digihaler.
By Drug Class
By Disease Type
By Distribution Channel
By End User
By Route of Administration
By Prescription Type
